Today more than 90% of healthcare professionals are on an Electronic Health Records (EHR), and more than five hours of an eight-hour day are spent in the EHR. In parallel, life sciences companies have become increasingly aware of the ability to harness EHR data to solve for numerous challenges both in the pre-approval and post-commercialization arenas.
Earlier this year, Precision Value & Health, in association with Precision ADVANCE, hosted an in-depth, live roundtable: The Future Treatment and Access Landscape for Cell and Gene Therapies
In partnership with Precision VH, this webinar is a virtual panel discussion where experts will describe and debate the contributions that Medical Affairs can make to early R&D (preclinical through Ph-IIb).
Congratulations to Suepattra May-Slater and the PRECISIONheor team for their contributions to a impactful study just published in the journal MDM Policy and Practice. The paper, entitled: "Estimating Productivity Loss from Breast and Non–Small-Cell Lung Cancer among Working-Age Patients and Unpaid Caregivers: A Survey Study Using the Multiplier Method" outlines the challenges in truly capturing the economic burden of cancer for both patients and their caregivers. The authors also suggest the need for more support in the workplace for these individuals, and a holistic approach to accounting for these impacts in treatment decision making.
Don’t miss any of our upcoming Precision Value & Health events! Check out our monthly marketing activities calendar to stay ahead of upcoming dates!
With focus in the COVID-19 pandemic shifting to treatments and managing severe forms of the disease, it's important to understand how health economists capture these dynamics to estimate the value of antiviral treatments. Precision's Jacquelyn W. Chou, Marissa Baker-Wagner, Marlon Graf, Zachary Heim, and T. Joseph Mattingly II provide recommendations for aligning the actual practice of value assessment of antivirals with best practice guidelines
One of the top tradeoffs faced by clinical stage biotech and pharmaceutical firms in raising capital to fund their clinical trial programs is the question of when and how to build a commercialization strategy, including navigating the complex work of securing market access. Precision's Ross Maclean and co-author Liz Turner discuss three high-value tactics that should be conducted early to avoid costly missteps that could impact product success.
Emerging biotech organizations have had to become both resourceful and creative since the start of the COVID-19 pandemic. At the same time, Big Pharma and the medical device firms have turned around COVID-19 diagnostics, vaccines, and therapeutics at a stunningly impressive pace. The pressure on emerging and small biotech companies to do more with less and maximize results is only projected to continue. Precision's Ross Maclean and co-author Liz Turner identify seven key attributes that favor the smaller biotech.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
